Quarterly ResultMay 11, 2026, 04:13 PM
Eikon Therapeutics Q1 Net Loss $83M; Cash $596M; ASCO Data
AI Summary
Eikon Therapeutics reported a net loss of $83.0 million for the first quarter of 2026, an increase from $74.5 million in the prior-year period. Despite the increased loss, the company maintained a strong financial position with $596.0 million in cash, cash equivalents, and marketable securities as of March 31, 2026, expected to fund operations into the second half of 2027. The company also announced significant clinical progress, with six abstracts accepted for the ASCO annual meeting, highlighting new safety, tolerability, and efficacy data from its lead oncology programs EIK1001, EIK1003, and EIK1005.
Key Highlights
- Cash, cash equivalents, and marketable securities were $596.0 million as of March 31, 2026.
- Net loss attributable to common stockholders was $83.0 million for Q1 2026, compared to $74.5 million for Q1 2025.
- Research and Development expenses increased 24% to $70.0 million for Q1 2026 from $56.6 million in Q1 2025.
- General and Administrative expenses increased 17% to $17.3 million for Q1 2026 from $14.8 million in Q1 2025.
- Six abstracts were accepted for the American Society of Clinical Oncology (ASCO) annual meeting.
- EIK1001 Phase 2 trial in NSCLC showed 60% ORR and 89% DCR in non-squamous cohort (N=53).
- EIK1001 Phase 2 trial in NSCLC showed 71% ORR and 100% DCR in squamous cohort (N=17).
- EIK1003 monotherapy showed 14.3% ORR (7/49 evaluable patients) in Phase 1/2 trial.
Price Impact
More from EIKN